Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Table 7

Ongoing lenalidomide-maintenance trials.

Name	Phase	Age	Histology	Drugs	Status
NCT01035463	I/II	>19 ys	Relapsed or refractory NHL	R-BEAM + ASCT + mL	Ongoing and recruiting
NCT01035463	I/II	>18 ys	Relapsed or refractory NHL	R-BEAM + ASCT + mL	Ongoing and recruiting
NCT01254578	I	>18 ys	High-risk hematologic cancers after Allo-SCT	mL	Ongoing and recruiting
NCT01045928	I/II	>18 ys	NHL	R + mL	Ongoing not recruiting
NCT01021423	III	>18 ys	Untreated MCL	FCR or R-CHOP + mL	Ongoing not recruiting
IIL MCL0208	III	18–60 ys	Untreated MCL	R-BEAM + ASCT + mL	Ongoing and recruiting

R-BEAM: rituximab, BCNU, etoposide, ara-C, melphalan; ASCT: autologous stem cell transplantation; mL: lenalidomide maintenance; R: rituximab; FCR: fludarabine, cyclophosphamide; rituximab; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.